# Study of Haemodialysis Patients Switching From Aranesp to Biosimilar

> **NCT02191150** · — · COMPLETED · sponsor: **Amgen** · enrollment: 272 (actual)

## Conditions studied

- Anaemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02191150
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-04
- **Final completion:** 2015-05
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2016-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02191150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02191150, "Study of Haemodialysis Patients Switching From Aranesp to Biosimilar". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02191150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*